Immunicum AB

April 22, 2013

NASDAQ OMX (NASDAQ: NDAQ) announces that today Immunicum AB (short name: IMMU) shares started trading on First North at NASDAQ OMX Stockholm. Immunicum belongs to the Healthcare sector and is the fifth new company to be admitted to trading on First North in 2013.

Immunicum develops cancer immunotherapies. The company’s two main groups of therapeutic cancer vaccines, SUBCUVAX™ and INTUVAX™, in addition to the method for expansion of tumor-specific T-cells (CD70), are based on the Nobel Prize awarded discovery of dendritic cells (DCs) and their central role in all immune responses. Since the raw material consists of white blood cells (DCs) from healthy donors, Immunicum’s products can be produced in large scale. For more information, visit www.immunicum.se and follow the Immunicum share here.


Interview with Immunicum CEO Jamal El-Mosleh (Swedish only) (2:20).


Jamal El-Mosleh, CEO of Immunicum is welcomed by Emelie Jarnesten, NASDAQ OMX


From the left: Alex Karlsson-Parra, Board member and Founder, Jamal El-Mosleh, CEO and Per-Olof Gunnarsson, CFO of Immunicum tolls the bell to open the market.


Jamal El-Mosleh signs the NASDAQ OMX guestbook.


The Immunicum team together with their certified adviser, G&W Fondkommission and the NASDAQ OMX team.